Delaware Chapter of the American College of CardiologyOur purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments. |
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- PFA Matches RFA on PVI Durability, Shows Low AE Rates in Registry DataTwo studies published in JACC: Clinical Electrophysiology on June 29 provide new insights on the durability of pulmonary vein isolation (PVI) with pulsed field ablation (PFA) vs. radiofrequency ablation (RFA) in patients with persistent atrial fibrillation (AFib), as well as the safety profile of PFA among patients undergoing their first ablation for AFib.
- Eagle’s Eye View: Can Sugar-Sweetened Beverages and Fruit Juice Lead to Hypertension?In this week’s View, Dr. Eagle looks at withdrawing guideline-directed medical therapy (GDMT) for patients with atrial fibrillation (AF).
- Lower Ambient Temperature Associated With Greater SCA Risk at Marathon Races in JapanRunners participating in Japanese marathon races largely held in autumn and winter had a greater risk of sudden cardiac arrest (SCA) when the ambient temperature was lower at race start, while no significant relationship between ambient air pollutants and SCA risk was identified, according to a study published June 30 in JACC: Advances.
- Mechanical Leaflet Splitting is Feasible in High-Risk Patients Undergoing Valve-in-Valve TAVRMechanical leaflet splitting in patients with anatomically high-risk undergoing valve-in-valve (ViV) TAVR saw high procedural success, according to a study published June 25 in JACC: Cardiovascular Interventions.
- ACCEL Lite: Cardiorenal Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Diabetes and CVDIn this interview, Matthew Martinez, MD, FACC and Steven E. Nissen, MD, MACC examine the SURPASS-CVOT Randomized Clinical Trial.



